We are live on ! Find out more
CVS icon

CVS Health

1,654 hedge funds and large institutions have $54.6B invested in CVS Health in 2019 Q2 according to their latest regulatory filings, with 123 funds opening new positions, 754 increasing their positions, 660 reducing their positions, and 154 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more funds holding in top 10

Funds holding in top 10: 3548 (+13)

14% more repeat investments, than reductions

Existing positions increased: 754 | Existing positions reduced: 660

1% less capital invested

Capital invested by funds: $55.1B → $54.6B (-$425M)

1.44% less ownership

Funds ownership: 78.75%77.31% (-1.4%)

3% less funds holding

Funds holding: 1,7081,654 (-54)

20% less first-time investments, than exits

New positions opened: 123 | Existing positions closed: 154

20% less call options, than puts

Call options by funds: $1.14B | Put options by funds: $1.44B

Holders
1,654
Holders Change
-54
Holders Change %
-3.16%
% of All Funds
35.92%
Holding in Top 10
48
Holding in Top 10 Change
+13
Holding in Top 10 Change %
+37.14%
% of All Funds
1.04%
New
123
Increased
754
Reduced
660
Closed
154
Calls
$1.14B
Puts
$1.44B
Net Calls
-$291M
Net Calls Change
+$32.6M
Name Holding Trade Value Shares
Change
Change in
Stake
VHAM
351
Van Hulzen Asset Management
California
$8.66M +$767K +14,235 +10%
NLGIA
352
Nippon Life Global Investors Americas
New York
$8.56M +$1.2M +22,200 +16%
LIM
353
Lathrop Investment Management
Arkansas
$8.55M +$337K +6,249 +4%
DnB Asset Management
354
DnB Asset Management
Norway
$8.52M -$262K -4,858 -3%
RGI
355
River Global Investors
United Kingdom
$8.43M +$1.24M +23,061 +18%
HCM
356
Horan Capital Management
Maryland
$8.42M -$123K -2,276 -1%
TBA
357
Tower Bridge Advisors
Pennsylvania
$8.4M -$1.7M -31,513 -17%
Kovitz Investment Group Partners
358
Kovitz Investment Group Partners
Illinois
$8.38M +$832K +15,454 +11%
HCMT
359
Highland Capital Management (Tennessee)
Tennessee
$8.29M -$1.06M -19,649 -11%
Creative Planning
360
Creative Planning
Kansas
$8.28M +$470K +8,719 +6%
NAM
361
Nissay Asset Management
Japan
$8.23M -$72.4K -1,344 -0.9%
MTC
362
McDaniel Terry & Co
Texas
$8.18M +$204K +3,787 +3%
CIC
363
Canal Insurance Company
South Carolina
$8.17M
AssetMark Inc
364
AssetMark Inc
California
$8.14M +$2.76M +51,229 +52%
BRA
365
Biechele Royce Advisors
Indiana
$8.13M +$1.74M +32,379 +28%
VanEck Associates
366
VanEck Associates
New York
$8.11M -$65.1K -1,209 -0.8%
RMCM
367
Reynders McVeigh Capital Management
Massachusetts
$8.07M -$196K -3,647 -2%
MCM
368
MAI Capital Management
Ohio
$8.01M +$2.15M +39,840 +37%
HTHT
369
Hemenway Trust Hemenway Trust
New Hampshire
$8M -$13.8K -256 -0.2%
BC
370
Brinker Capital
Pennsylvania
$7.97M -$1.13M -21,075 -13%
N
371
Natixis
France
$7.97M +$5.43M +100,774 +221%
RCYC
372
Richard C. Young & Co
Rhode Island
$7.92M +$478K +8,872 +7%
SW
373
SVB Wealth
Massachusetts
$7.91M +$971K +18,031 +14%
Brown Advisory
374
Brown Advisory
Maryland
$7.86M -$14.5M -269,661 -65%
BCM
375
Buckhead Capital Management
Georgia
$7.79M +$229K +4,256 +3%

CVS Hedge Fund Activity: Q2 2019 in Review

1,654 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in CVS Health (CVS) for Q2 2019, worth a combined $54.6B — down 0.77% from $55.1B a quarter earlier.

Sellers outnumbered buyers: 154 funds closed out of CVS and 123 opened new positions — a net loss of 31 holders — while 660 trimmed existing stakes and 754 added.

The largest buyer was Nuveen, adding an estimated $648M. The largest seller was T. Rowe Price Associates, cutting an estimated $321M.

  • 1,654 institutional investors held CVS Health (CVS) as of Q2 2019, down from 1,708 in Q1 2019.
  • Funds reported $54.6B of CVS Health stock for Q2 2019, down 0.77% quarter-over-quarter.
  • 123 funds opened new CVS Health positions in Q2 2019 and 154 closed out, a net change of -31 holders.
  • The largest CVS Health buyer in Q2 2019 was Nuveen, an estimated $648M added.
  • The largest CVS Health seller in Q2 2019 was T. Rowe Price Associates, an estimated $321M sold.

Based on aggregated 13F filings for Q2 2019.